Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
In order to face the challenges that the companies have in the Viral Gastroenteritis Market, corporations often use diverse market share positioning strategies for addressing the complicatedness of the common viral infection affecting the gastrointestinal tract. Strategies such as diversification has become the paramount in brands developing advanced innovative and specific treatments for viral gastroenteritis. This can be in the form of contributing funds to research and development that would be focused on creating specialized antiviral medicines, vaccines, and supportive care protocols that would have a higher success rate and provide better therapeutic results to patients. Unique products – with an open door to market leaders – would look after the varied cases of viral gastroenteritis, from treatment of disease to general provision of supportive care to patients and healthcare providers.
Apart from Cost leadership, the strides in the economy of gastrointestinal pathogens is another critical aspect of the Virus Gastroenteritis, understanding of/awareness about the prices and accessibility of health insurance. Manufacturers focus on the reduction of cost and improve the scale of production in order to produce medicines at cheaper prices, thus attracting more people in need by providing them with access to this effective therapy. This plan provides for product line assortment, production simplification, seller agreements, warehouse optimization, and huge subsidy plans. And coming up with cost-competitive solutions enables companies to deal with not only the financial problem but also stand out from the crowd in the market.
Market penetration has been not only a significant player in the market but also as a means for encouraging the growth of market share of the Viral Gastroenteritis market. These efforts include more intensive promotion of existing brand to the initiatives of targeted marketing campaigns and working hand to hand with other healthcare professionals to convince them the claiming for the viral gastroenteritis product of theirs. Through acquisition of a greater market, companies gain access to economies of scale, use data-driven insights on prescribing, which ensures market dominance as they emerge competent in providing effective solutions for the condition.
Besides that, this strategy is opposed by market development which aims at entering new geographic areas or population segments. It can be achieved by modifying the existing therapies to treat the specific patient groups or by entering untouched regions where the never-ending need for the solutions providing a viral gastroenteritis management has been observed for some time. Market development empowers a company to tap into new markets; and also helps them in the diversification, providing an opportunity to cash in on the arising trends in the world of viral gastroenteritis treatment.
Strategies like Partnerships and Collaborations are among the key successful steps which companies use during their Viral Gastroenteritis Market positioning. Partnerships with healthcare providers, researches/health public institutions and governmental health agencies enable exchange of ideas, creation of capital/resources pooling and development of new treatments together.
Viral Gastroenteritis Market Highlights:
Viral Gastroenteritis Market Market Overview
The Viral Gastroenteritis Market is anticipated to reach USD 6,4772.93 Million by 2030 at 4.40% CAGR during the forecast period 2022-2030. Viral gastroenteritis, also known as stomach flu, is inflammation of the lining of the stomach, small intestine, and large intestine. There are a number of viruses leading viral gastroenteritis such as norovirus, rotavirus, astrovirus and enteric adenovirus. Norovirus and rotavirus are the most common causes of this disease. This disease is transmitted through direct contact with the patient, and contaminated water or food. The main focus of treating the disease is rehydration by drinking enough water or fluids.
The market for viral gastroenteritis is driven by an increasing prevalence of gastrointestinal diseases, availability of cost effective treatment and extensive research and development activities in internal medicine Furthermore, there is an increasing demand for the new drugs for the treatment of the disease.
Bacterial resistance to commonly used antibiotics such as penicillin and amoxicillin may be the leading restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrant in the market.
According to the World Health Organization (WHO), diarrheal diseases are a major cause of hospitalizations and child deaths globally.
FIGURE 1: Global Viral Gastroenteritis Market by Region, 2016 (%) 
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Key Players in the Global Viral Gastroenteritis Market Valeant Pharmaceuticals International Inc. (U.S.), Janssen Global Services, LLC U.S.), Takeda Pharmaceutical (Japan), Bayer AG (Germany), Sanofi (France), Allergan (Ireland), GlaxoSmithKline (U.S.), Abbott (U.S.),  and AstraZeneca (U.K). Segments                                                                      The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.
On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.
On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.
On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.
On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.
On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Â
Â
Regional Analysis of the Global Viral Gastroenteritis Market   America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center For Disease Control And Prevention (CDC), each year on average in the United States, there are 19 to 21 million cases of acute gastroenteritis.
Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.
In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostic tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will propel the growth of the Asia Pacific market.
The Middle East & Africa also show a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection.
 Intended Audience
-
Gastrointestinal Drug Manufacturers - Gastrointestinal Drug Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
